Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
40 hedge funds and large institutions have $35M invested in Turnstone Biologics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
11% more funds holding
Funds holding: 36 → 40 (+4)
6% more capital invested
Capital invested by funds: $33.1M → $35M (+$1.83M)
1.33% more ownership
Funds ownership: 56.46% → 57.79% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.03M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$823K |
| 4 |
ZP
Zimmer Partners
New York
|
+$374K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$332K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.78M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$716K |
| 3 |
CCM
CAAS Capital Management
New York
|
-$117K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$42K |
| 5 |
Morgan Stanley
New York
|
-$22.3K |
TSBX Hedge Fund Activity: Q1 2024 in Review
40 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q1 2024, worth a combined $35M — up 5.5% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TSBX positions and 1 closed out — a net gain of 4 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $1.03M. The largest seller was Fidelity Investments, cutting an estimated $2.78M.
- 40 institutional investors held Turnstone Biologics (TSBX) as of Q1 2024, up from 36 in Q4 2023.
- Funds reported $35M of Turnstone Biologics stock for Q1 2024, up 5.5% quarter-over-quarter.
- 5 funds opened new Turnstone Biologics positions in Q1 2024 and 1 closed out, a net change of +4 holders.
- The largest Turnstone Biologics buyer in Q1 2024 was BlackRock, an estimated $1.03M added.
- The largest Turnstone Biologics seller in Q1 2024 was Fidelity Investments, an estimated $2.78M sold.
Based on aggregated 13F filings for Q1 2024.